These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 21451526)
21. Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis. Fang IM; Lin CP; Yang CM; Chen MS; Yang CH Mol Vis; 2005 Jul; 11():443-51. PubMed ID: 16030495 [TBL] [Abstract][Full Text] [Related]
22. RANKL-induced down-regulation of CX3CR1 via PI3K/Akt signaling pathway suppresses Fractalkine/CX3CL1-induced cellular responses in RAW264.7 cells. Saitoh Y; Koizumi K; Sakurai H; Minami T; Saiki I Biochem Biophys Res Commun; 2007 Dec; 364(3):417-22. PubMed ID: 17963723 [TBL] [Abstract][Full Text] [Related]
23. Down-regulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice. Ren T; Chen Q; Tian Z; Wei H Biochem Biophys Res Commun; 2007 Dec; 364(4):978-84. PubMed ID: 17971299 [TBL] [Abstract][Full Text] [Related]
24. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Lucas AD; Bursill C; Guzik TJ; Sadowski J; Channon KM; Greaves DR Circulation; 2003 Nov; 108(20):2498-504. PubMed ID: 14581400 [TBL] [Abstract][Full Text] [Related]
25. Fractalkine and its receptor mediate extracellular matrix accumulation in diabetic nephropathy in mice. Song KH; Park J; Park JH; Natarajan R; Ha H Diabetologia; 2013 Jul; 56(7):1661-9. PubMed ID: 23604552 [TBL] [Abstract][Full Text] [Related]
26. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. Wasmuth HE; Zaldivar MM; Berres ML; Werth A; Scholten D; Hillebrandt S; Tacke F; Schmitz P; Dahl E; Wiederholt T; Hellerbrand C; Berg T; Weiskirchen R; Trautwein C; Lammert F J Hepatol; 2008 Feb; 48(2):208-15. PubMed ID: 18078680 [TBL] [Abstract][Full Text] [Related]
27. CX3CR1 reduces kidney fibrosis by inhibiting local proliferation of profibrotic macrophages. Engel DR; Krause TA; Snelgrove SL; Thiebes S; Hickey MJ; Boor P; Kitching AR; Kurts C J Immunol; 2015 Feb; 194(4):1628-38. PubMed ID: 25595779 [TBL] [Abstract][Full Text] [Related]
28. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Damås JK; Boullier A; Waehre T; Smith C; Sandberg WJ; Green S; Aukrust P; Quehenberger O Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2567-72. PubMed ID: 16224053 [TBL] [Abstract][Full Text] [Related]
29. Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease? Cormican S; Griffin MD Front Immunol; 2021; 12():664202. PubMed ID: 34163473 [TBL] [Abstract][Full Text] [Related]
30. The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Nevo I; Sagi-Assif O; Meshel T; Ben-Baruch A; Jöhrer K; Greil R; Trejo LE; Kharenko O; Feinmesser M; Yron I; Witz IP Cancer Lett; 2009 Jan; 273(1):127-39. PubMed ID: 18778890 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of the chemokine-receptor duo fractalkine/CX3CR1: an update. D'Haese JG; Friess H; Ceyhan GO Expert Opin Ther Targets; 2012 Jun; 16(6):613-8. PubMed ID: 22530606 [TBL] [Abstract][Full Text] [Related]
33. Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Kikuchi Y; Ikee R; Hemmi N; Hyodo N; Saigusa T; Namikoshi T; Yamada M; Suzuki S; Miura S Nephron Exp Nephrol; 2004; 97(1):e17-25. PubMed ID: 15153757 [TBL] [Abstract][Full Text] [Related]
34. CCR5 deficiency does not reduce hypertensive end-organ damage in mice. Krebs C; Fraune C; Schmidt-Haupt R; Turner JE; Panzer U; Quang MN; Tannapfel A; Velden J; Stahl RA; Wenzel UO Am J Hypertens; 2012 Apr; 25(4):479-86. PubMed ID: 22258337 [TBL] [Abstract][Full Text] [Related]
35. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in periodontal diseased tissue. Hosokawa Y; Nakanishi T; Yamaguchi D; Nakae H; Matsuo T Clin Exp Immunol; 2005 Mar; 139(3):506-12. PubMed ID: 15730397 [TBL] [Abstract][Full Text] [Related]
36. Chemokine fractalkine mediates leukocyte recruitment to inflammatory endothelial cells in flowing whole blood: a critical role for P-selectin expressed on activated platelets. Schulz C; Schäfer A; Stolla M; Kerstan S; Lorenz M; von Brühl ML; Schiemann M; Bauersachs J; Gloe T; Busch DH; Gawaz M; Massberg S Circulation; 2007 Aug; 116(7):764-73. PubMed ID: 17679613 [TBL] [Abstract][Full Text] [Related]
37. Fractalkine/CX3CR1 and atherosclerosis. Liu H; Jiang D Clin Chim Acta; 2011 Jun; 412(13-14):1180-6. PubMed ID: 21492740 [TBL] [Abstract][Full Text] [Related]
38. Expression of fractalkine (CX3CL1) and its receptor in endotoxin-induced uveitis. Chu L; Li X; Yu W; Qian T; Qi H; Huang L; Xu Y Ophthalmic Res; 2009; 42(3):160-6. PubMed ID: 19648777 [TBL] [Abstract][Full Text] [Related]
39. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Verge GM; Milligan ED; Maier SF; Watkins LR; Naeve GS; Foster AC Eur J Neurosci; 2004 Sep; 20(5):1150-60. PubMed ID: 15341587 [TBL] [Abstract][Full Text] [Related]
40. Protective roles of CX3CR1-mediated signals in toxin A-induced enteritis through the induction of heme oxygenase-1 expression. Inui M; Ishida Y; Kimura A; Kuninaka Y; Mukaida N; Kondo T J Immunol; 2011 Jan; 186(1):423-31. PubMed ID: 21131421 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]